November 18th, 2026mAbxience Backs OncoPrecision ADC With Investment, Manufacturing DealmAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.Read more